Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

NCT06454968 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Orelabrutinib, obinutuzumab, lenalidomide

Sponsor

Peking Union Medical College Hospital